CRISPR gene editing has transitioned from a laboratory curiosity to a cornerstone of modern biotechnology, revolutionizing our approach to genetic diseases, including Charcot-Marie-Tooth (CMT) disease ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

The U.S. Food and Drug Administration says it's aware of “do-it-yourself” kits for producing gene therapies for ...

CRSP’s main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It’s a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy’s rollout has been slow ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

For a decade after its discovery, CRISPR gene editing was stuck on the cusp of transforming medicine. Then, in 2023, scientists started using it on sickle-cell disease, and Victoria Gray, a patient ...